Competitive group I metabotropic glutamate receptor antagonist and inhibitor of phosphoserine phosphatase.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 169.07. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||5.91 mL||29.57 mL||59.15 mL|
|5 mM||1.18 mL||5.91 mL||11.83 mL|
|10 mM||0.59 mL||2.96 mL||5.91 mL|
|50 mM||0.12 mL||0.59 mL||1.18 mL|
References are publications that support the products' biological activity.
Evans et al (1982) The effect of a series of ω-phosphonic-α-carboxylic amino acids on electrically evoked and amino acid induced responses in isolated spinal cord preparations. Br.J.Pharmacol. 75 65 PMID: 7042024
Hawkinson et al (1996) The metabotropic glutamate receptor antagonist L-2-amino-3-phosphonopropionic acid inhibits phosphoserine phosphatase. Eur.J.Pharmacol. 307 219 PMID: 8832224
Saugstad et al (1995) L-2-Amino-3-phosphonopropionic acid completely antagonizes metabotropic glutamate receptors 1α and 5 in Xenopus oocytes. Eur.J.Pharmacol. 289 395 PMID: 7621916
If you know of a relevant reference for DL-AP3, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: DL-AP3, supplier, Phosphoserine, phosphatase, inhibitors, inhibits, Group, I, mGlur, antagonists, Protein, Ser/Thr, Phosphatases, Receptors, mGlu1, mGlu5, mGluR1, mGluR5, Glutamate, Metabotropic, Glutamate, (Metabotropic), Group, I, Receptors, Protein, Ser/Thr, Phosphatases, Glutamate, (Metabotropic), Group, I, Receptors, Tocris Bioscience
1 Citation for DL-AP3
Citations are publications that use Tocris products. Selected citations for DL-AP3 include:
Vance et al (2015) PAR1-activated astrocytes in the nucleus of the solitary tract stimulate adjacent neurons via NMDA receptors. J Neurosci 35 776 PMID: 25589770
Do you know of a great paper that uses DL-AP3 from Tocris? If so please let us know.
Average Rating:(Based on 0 Reviews)
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.